Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Non-adherence of CML patients

    Results of the global adherence survey of the CML Advocates Network
    Giora Sharf, CML Advocates Network


    Issues covered:

    • Results of the global adherence survey of 2546 CML patients from 79 countries
    • Intentional and non-intentional non-adherence levels
    • Differences between countries, type of TKI, administration schedule, age groups, perception of quality of life and side effects
    • Tools to drive adherence and importance of routine


    Click on the "Play" button below to hear the slidecast. Be sure to turn on your speakers to hear the audio!


    Please share your feedback below, and view the other Virtual Education Program modules.


    Facteur de variabilité de la réponse au ITK</li>
                  <li>Les trois grand mécanismes de résistance</li>
                  <li>La réponse au traitement</li>
                  <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

    Has this been helpful? Please provide your comments here: